Feb 24, 2022 / 04:00PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
Great. Well, thank you all for joining us here at the Citi Healthcare Conference. I'm Patrick Donnelly. I cover the tools, diagnostics and CROs here at Citi. Happy to have the IQVIA team with us, its CFO and the IR team. And Ron, thanks so much for being with us.
Questions and Answers:
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior AnalystMaybe to start, not surprisingly, on this topic, the biotech funding world has been in very much focus over the past couple of weeks. So can you maybe give us a sense to your exposure to that pre-commercial biotech funding world? Are you seeing any impact or slowdown to your business? And then just remind us, I mean how about the EBP definition, what that means in terms of revenue, R&D spend. And how that compares to maybe one of your peers who put out that kind of down 25% in January commentary and kind of spooked the market a little bit? It would be great to dive into that to start.
Ronald E.
Trustpilot
